43 results about "Hemolytic Agents" patented technology

A kit for quantitative analysis of C-reactive protein (CRP) according to an embodiment of the present application may comprise: a first composition comprising a hemolytic agent for hemolyzing at least a portion of blood cells in a blood sample; and a second composition comprising an anti-CRP antibody for the antigen-antibody reaction of the CRP contained in the hemolyzed sample. The CRP quantitative analysis kit of the present application can provide a stabilizer which enables a solid-phase dry anti-CRP antibody to be sufficiently redissolved to participate in an immune reaction, so that quantitative analysis of CRP can be highly accurately and accurately performed in a wide concentration range, and storage stability is improved.

The present application relates to the field of biotechnology, and specifically discloses a kit for preparing a glycated hemoglobin control product, a method for preparing a glycated hemoglobin control product, and a kit. The kit for preparing a glycated hemoglobin control product comprises: a cell washing solution comprising: a buffer, an osmotic pressure maintaining agent; a saccharification solution comprising: a buffer, an osmotic pressure maintaining agent, and glucose; a hemolytic agent comprising: a buffer, a first surfactant; and a lyophilization protectant comprising: a buffer, an osmotic pressure maintaining agent, a stabilizer, and a second surfactant. Through the above-mentioned method, the glycated hemoglobin control product has the characteristics of low cost, high accuracy, good uniformity, and strong stability. The use of the glycated hemoglobin control product can meet the purpose of quality control of the adapted glycated hemoglobin meter system, and the obtained results are accurate and reliable.

The application relates to a biochemical analyzer and a detection method for detecting glycated hemoglobin. The hemoglobin concentration and the glycated hemoglobin concentration of a to-be-detected whole blood sample are obtained, and the content proportion of the glycated hemoglobin is calculated according to the hemoglobin concentration and the glycated hemoglobin concentration. The hemoglobin concentration is obtained by the following steps: obtaining a first absorbance of a to-be-detected sample liquid at a hemoglobin measurement wavelength, wherein the to-be-detected sample liquid is prepared by mixing a to-be-detected whole blood sample, a hemolytic agent and a hemoglobin detection reagent; obtaining at least two second absorbances of the to-be-detected sample liquid at at least two different correction wavelengths, wherein the correction wavelengths are designed so that the absorbance of a lipid interferent at the correction wavelength is greater than the absorbance of hemoglobin at the correction wavelength; correcting the first absorbance according to the second absorbance; and determining the hemoglobin concentration according to the corrected first absorbance. The application can improve the accuracy of hemoglobin detection.

The present invention provides a method for detecting hemoglobin concentration and a blood cell analyzer, wherein the method comprises: detecting a first test sample injected into a reaction cell and obtaining a first HGB value; wherein the first test sample comprises a diluent, a blood sample, and a first hemolytic agent; detecting a second test sample injected into the reaction cell and obtaining a second HGB value; wherein the second test sample is obtained by adding the second hemolytic agent to the first test sample in the reaction cell and mixing them; and selecting the minimum of the first and second HGB values as the HGB value of the blood sample. Because the presence of bubbles during the detection process can lead to an inflated HGB value, the present application proposes selecting the minimum of the first and second HGB values as the HGB value of the blood sample. This minimizes the impact of bubbles on the HGB value and improves the accuracy of the HGB detection result.

The utility model discloses a built-in hemolytic agent bottle and hematology analyzer relates to medical instrument technical field, wherein the built-in hemolytic agent bottle includes solvent bottle, movable joint block and pipeline subassembly, solvent bottle includes mutually communicated bottle body and bottle cap, bottle body and bottle cap detachable connection, bottle cap far away from bottle body side is equipped with the movable mouth; the movable connector block is movably arranged at the movable opening, the movable connector block and the movable opening are arranged in a clearance mode, and the movable connector block is provided with a mounting hole which is formed in the thickness direction in a penetrating mode; the pipeline assembly is fixedly arranged at the mounting hole, one end of the pipeline assembly extends into the bottle body, and the other end of the pipeline assembly penetrates out of the mounting hole and is communicated with an external liquid system. According to the technical scheme, the problem that when a bottle cap of an existing built-in hemolytic agent bottle is screwed down, a pipeline is prone to being bent is solved.

The utility model discloses a hemolytic agent refrigeration device. The hemolytic agent refrigeration device comprises a refrigerator main body, a placing frame and a guide plate, a refrigeration cavity is formed in the refrigerator body, an opening is formed in one side of the refrigerator body, a sealing door is installed on the refrigerator body in an opening and closing mode, and a plurality of universal wheels are installed at the bottom of the installation frame. The guide plate is installed at the lower end of the side, close to the opening, of the refrigerator body through a storage driving structure. According to the hemolytic agent cold storage device, the hemolytic agent packaging container is placed through the placing frame, the unfolded guide plate is matched, hemolytic agents placed on the placing frame can be conveniently pushed into the refrigerator body to be refrigerated, after the placing frame enters the refrigerator body, the guide plate can be automatically stored by starting the storage driving structure, and the hemolytic agent cold storage device is convenient to use. Compared with the prior art, human input is effectively reduced, and cold storage of the hemolytic agent is facilitated.

The invention relates to a pretreatment method of a blood culture solution for microorganism mass spectrum identification, which comprises the following steps: fully and uniformly mixing a hemolytic agent with the blood culture solution which comprises blood cells and at least one microorganism; centrifuging and filtering to obtain a microbial precipitate; wherein the hemolytic agent is used for dissolving blood cells without destroying microorganisms, the hemolytic agent comprises a nonionic surfactant, the nonionic surfactant is selected from one or more compounds shown in the formula (I), and R1 is selected from hydrogen and C1-C8 alkyl; r2 is selected from a C8-C20 fatty alcohol group, a C8-C20 fatty acid group and a C8-C20 fatty amine group; and n is 5-30. According to the method, blood cells can be rapidly dissolved, the solution viscosity and bubbling cannot be increased, the microbial separation efficiency is improved, and the microbial mass spectrum identification speed is increased.

The invention relates to a blood cell analyzer and a blood cell analysis method. Sucking a to-be-detected blood sample; mixing a part of the blood sample to be detected, a hemolytic agent and a first fluorescent staining agent to prepare a first measurement sample, and detecting first optical information of particles in the first measurement sample; mixing the other part of the blood sample to be measured, the diluent and a second fluorescent staining agent to prepare a second measurement sample, and detecting second optical information of particles in the second measurement sample; acquiring first leukocyte classification information based on the first optical information; when it is judged that classification abnormity exists in the first leukocyte classification scatter diagram, second leukocyte classification information is obtained based on the second optical information, and the second leukocyte classification information is used for correcting the first leukocyte classification information. According to the invention, an accurate leukocyte classification result can be obtained.

The disclosure provides a sample testing method and a sample analyzer, the method including: obtaining a sample to be tested; providing a reagent, the reagent including a hemolytic agent, a first fluorescent dye and a third fluorescent dye; mixing the sample and the reagent to form a sample solution; making the sample solution flow in a flow cell in a single test, irradiating the particles by using a first light source and a second light source, and detecting scattered light signals, first fluorescence signals and third fluorescence signals; obtaining a classification result and / or a counting result of white blood cells in the sample to be tested based on the first fluorescence signals and the scattered light signals; and obtaining a counting result of nucleated red blood cells in the sample to be tested based on the third fluorescence signals and the scattered light signals.

The application discloses a blood sample distribution method and a blood sample distribution device. The blood sample distribution method comprises the following steps: obtaining an initial blood sample by a sampling needle; adding a hemolytic agent into a DIFF reaction pool; distributing the initial blood sample into the DIFF reaction pool by the sampling needle to prepare a DIFF reaction liquid; adding a diluent into a WBC reaction pool and distributing the initial blood sample into the WBC reaction pool by the sampling needle to prepare a second sample liquid; cleaning the inner wall and the outer wall of the sampling needle; sucking the second sample liquid from the WBC reaction pool by the sampling needle; adding the hemolytic agent into the WBC reaction pool to prepare a WBC reaction liquid; adding the diluent into an RBC reaction pool and distributing the second sample liquid into the RBC reaction pool by the sampling needle to prepare an RBC reaction liquid. The blood sample distribution method changes the blood distribution sequence of the initial blood sample, and the blood sample is first distributed into the DIFF reaction pool which has a lower requirement for the quantitative accuracy of the blood sample, so that the blood throwing operation is not needed, the blood sample consumption is reduced, and the consumption of the cleaning reagent is saved.

The embodiments of the present application relate to a platelet counting method and a blood cell analyzer. The method comprises: aspirating a blood sample to be tested; mixing one portion of said blood sample with a diluent to prepare a first test sample, and mixing the other portion of said blood sample with a hemolytic agent and fluorescent dye to prepare a second test sample; performing impedance measurement on the first test sample, in order to obtain an electrical signal of the first test sample; performing optical measurement on the second test sample, in order to obtain at least one optical signal from among a scattered light signal and a fluorescent light signal of the second test sample; at least on the basis of the electrical signal of the first test sample, obtaining platelet distribution information of said blood sample; and at least on the basis of the pulse width of an optical signal among the at least one optical signal that corresponds to platelets in the second test sample, and the platelet distribution information, obtaining a platelet count value. Thus, an accurate platelet count can be obtained at a low cost.

The present invention has discovered that DO3A-based substances containing gadolinium complexes, which are conventionally used as anti-inflammatory agents, have a novel effect of inhibiting thrombin-induced thrombosis or dissolving blood, without being involved in the platelet action function of stopping bleeding at an injury or wound site, and discloses the applicability of DO3A-based substances containing gadolinium complexes to novel uses as thrombosis inhibitors or blood coagulants.

According to the hematuria microscopic examination method, the urine detection reagent, the chip and the hematuria evaluation parameters, urine is diluted by M times to obtain a microscopic examination sample; or adding a hemolytic agent into the urine to obtain a microscopic examination sample; adding a microscopic examination sample into a detection cavity A of the detection chip, wherein the cavity height of the detection cavity is HA; shooting an image of the detection cavity; the cavity area corresponding to the microscopic examination image is SA; target visible components in the microscopic examination image are recognized, and the number Kn of the target visible components is obtained; the unit volume number Pn of the target visible components is equal to M * Kn / (SA * HA); the target visible component comprises red blood cells. The method is suitable for quantitative analysis of urine samples which are high in blood component content in hematuria and cannot flatten all blood cells in microscopic examination. A microscopic examination sample is obtained after the hemolytic agent is added into the urine, red blood cells can be eliminated, the red blood cells are prevented from shielding other visible components, and the detection rate of other visible components in the urine is increased.

The invention relates to a blood cell analyzer and a blood cell analysis method. The method comprises the following steps: mixing a part of a sucked blood sample to be detected, a diluent and a fluorescent staining agent in a first reaction tank to prepare a first determination sample, and obtaining first optical information generated after particles in the first determination sample are irradiated by light; mixing the other part of the blood sample to be detected with a hemolytic agent in a second reaction tank to prepare a second determination sample, and obtaining colorimetric optical information of the second determination sample; obtaining a reticulocyte detection result, a platelet detection result, an erythrocyte detection result and a first leukocyte detection result of the to-be-detected blood sample based on the first optical information, wherein the first leukocyte detection result at least comprises a lymphocyte percentage, a mononuclear cell percentage and a granulocyte percentage; and determining the hemoglobin concentration of the to-be-detected blood sample based on the colorimetric method optical information. According to the application, the reagent cost required for obtaining the detection result of the to-be-detected blood sample can be reduced.

The invention discloses a tumor immunotherapy curative effect prediction kit based on bone marrow spleen neutrophil proportion, which comprises an anti-human CD62L-PE antibody, an anti-human CD11b-PE-Cy7 antibody, an anti-human CD44-APC antibody and an anti-human ICAM1-FITC antibody which are respectively used for marking neutrophil subgroups in a peripheral blood sample, and comprises a hemolytic agent which is used for removing red blood cells in the sample, according to the present invention, the structure is scientific and reasonable, the use is safe and convenient, the ratio of the bone marrow-derived neutrophil to the spleen-derived neutrophil, i.e. The M / S ratio, has the significant negative correlation with the treatment effect of the PD-1 inhibitor, and the kit designed based on the discovery can achieve the rapid and non-invasive immune response evaluation at the peripheral blood level, compared with an existing method depending on tissue biopsy or PD-L1 immunohistochemistry, the method has the advantages that the immune microenvironment state of a patient can be reflected more early and dynamically, and a precise curative effect prediction basis is provided for a PD-1 / PD-L1 inhibitor and a combination therapy thereof.

The embodiment of the invention relates to a sample analysis method of a sample analyzer. The sample analysis method comprises the following steps: sucking a to-be-detected blood sample; mixing at least one part of the blood sample to be detected, the hemolytic agent, the first fluorescent dye and the second fluorescent dye to prepare a detection sample at a time; in a single test, each particle in a measurement sample is passed through an optical detection zone irradiated by excitation light to acquire optical information of the measurement sample, the excitation light including light of a first wavelength capable of exciting a first fluorescent dye and light of a second wavelength capable of exciting a second fluorescent dye, the second wavelength being greater than the first wavelength, the optical information comprises a first fluorescent signal corresponding to the first fluorescent dye and a second fluorescent signal corresponding to the second fluorescent dye, which are obtained in a single test; and obtaining infected red blood cell information of the measurement sample based on the first fluorescence signal and the second fluorescence signal. Therefore, the infected red blood cell information can be quickly and accurately obtained to assist malaria diagnosis.

Disclosed is applicability in novel uses of a DO3A-based material containing a gadolinium complex as an antithrombotic agent or a coagulant, on the basis of a discovery finding that the DO3A-based material containing the gadolinium complex which has been used as an anti-inflammatory agent has a novel effect of suppressing a thrombus induced by thrombin or dissolving blood, without being involved in the function of platelet action which stops bleeding at a damaged or injured area.

This invention discloses a method, apparatus, medium, and device for determining insufficient hemolytic agent dosage. First, a set of pulse signals from a blood cell sample under a preset scattering angle is acquired. Then, the signal intensity of each pulse signal in the set is identified, and the particle distribution is statistically analyzed. Next, the rate of change of particle count for each type of signal intensity in the particle distribution is calculated to obtain the rate of change. Then, the zero-crossing points of the rate of change are searched for, and the maximum particle count and the minimum particle count associated with red blood cells are determined based on these points. Finally, the signal interference value is calculated based on the minimum and maximum particle counts. If the signal interference value is greater than an interference threshold, the current hemolytic agent dosage is determined to be insufficient. This invention can promptly remind testing personnel to check the remaining reagent level when significant interference is detected by monitoring the degree of red blood cell interference in the pulse signal.

This invention relates to a sample processing reagent and its application in flow cytometry analysis, belonging to the field of flow cytometry analysis technology. The invention provides a sample processing reagent comprising a hemolysin and a cell-permeable agent. The hemolysin comprises tris(hydroxymethyl)aminomethane (Tris), sodium chloride, calcium chloride, disodium ethylenediaminetetraacetate, paraformaldehyde, and a solvent. The cell-permeable agent comprises sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, nonylphenol polyoxyethylene ether, Triton X-100, paraformaldehyde, and a solvent. The hemolysin is mild and highly effective, providing complete hemolysis and clear cell clustering. The cell-permeable agent permeates the cell membrane under isotonic and neutral conditions, minimizing damage to cell surface antigens and effectively detecting both cytoplasmic and nuclear antigens.

The invention relates to the technical field of medical treatment, and particularly discloses a red breaking liquid for bloody body fluid cell wax blocks. The red breaking liquid is prepared from absolute ethyl alcohol and distilled water, and the volume concentration of the absolute ethyl alcohol is 20%-30%; according to the method, the ethanol aqueous solution in a specific concentration range is adopted as a splitting system, efficient and selective splitting of the red blood cells in the bloody body fluid is realized, and cell membranes of the seedless red blood cells can be quickly destroyed by utilizing the dissolution effect of ethanol on cell membrane lipid and the hypotonic characteristic of the solution, so that contents of the seedless red blood cells are released and are easily eluted. Meanwhile, the morphological integrity and cell membrane antigenicity of nucleated cells (including tumor cells) can be protected to the greatest extent, and the problem of cell damage or antigen shielding possibly caused by a conventional hemolytic agent is avoided.

The application discloses a kind of hemolytic agent underdosing judgment method, device, medium and equipment, by obtaining the particle distribution condition of signal intensity in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of

Disclosed is applicability in novel uses of a DO3A-based material containing a gadolinium complex as an antithrombotic agent or a coagulant, on the basis of a discovery finding that the DO3A-based material containing the gadolinium complex which has been used as an anti-inflammatory agent has a novel effect of suppressing a thrombus induced by thrombin or dissolving blood, without being involved in the function of platelet action which stops bleeding at a damaged or injured area.

The utility model relates to the technical field of medical instruments, and discloses a lightweight blood analysis device which comprises a detection module and a sample processing module. The sample treatment module comprises a multifunctional liquid suction needle for sucking liquid, a driving device and a dilution module; the multifunctional liquid suction needle is connected with the dilution module through the liquid path pipe, and the driving device controls the multifunctional liquid suction needle to move. The detection module comprises at least one sample position and a built-in reagent position, and the sample position and the built-in reagent position are both located in a moving track area of the multifunctional liquid suction needle. The multifunctional liquid suction needle is not only used for sucking a blood sample and diluting the blood sample for transferring, but also used for sucking and distributing a hemolytic agent and other detection reagents and distributing diluent. According to the design, the device structure and the process are greatly simplified, parts required by the device are greatly reduced, and the device cost and the failure rate are greatly reduced.

The embodiments of the present application relate to a sample analyzer and a sample analysis method. The sample analysis method comprises: aspirating a blood sample to be tested; mixing at least a portion of said blood sample, a hemolytic agent, a first fluorescent dye and a second fluorescent dye to prepare a measurement sample; in a single test, making each particle in the measurement sample pass through an optical detection zone irradiated by excitation light, so as to acquire optical information generated after each particle in the measurement sample has been irradiated by the excitation light, wherein the excitation light comprises light of a first wavelength capable of exciting the first fluorescent dye and light of a second wavelength capable of exciting the second fluorescent dye, and the second wavelength is greater than the first wavelength; on the basis of at least one scattered light signal and a first fluorescence signal, obtaining infected red blood cell information of the measurement sample; and on the basis of the at least one scattered light signal and a second fluorescence signal, obtaining a four-part white blood cell differential result of the measurement sample. Therefore, infected red blood cell information and a white blood cell differential result of a measurement sample can be obtained at the same time in a single test.

This invention discloses a detection kit and method for abnormal lymphocytes, myeloid blast cells, and acute promyelocytic leukemia. The detection kit includes a first reagent and a second reagent. The first reagent includes a hemolysin and a staining agent. The second reagent includes a hemolysin, a staining agent, and an antibody treatment agent, including CD13 and CD34 antibody treatment agents. The hemolysin, based on a total volume of 1L, includes the following components: 0.1-10g castor oil polyoxyethylene ether nonionic surfactant, 0.01-10g cationic surfactant, 0.5-15g buffer, 0.01-8g preservative, with the remainder being water. The pH value of the hemolysin is 5-9. The staining agent, based on a total volume of 1L, includes the following components: 0.001-0.2g nucleic acid dye, with the remainder being a solvent. The detection method includes: obtaining a blood sample to be tested, preparing a first sample, testing the first sample, preparing a second sample, and testing the second sample. This invention can accurately detect abnormal lymphocytes, myeloid blast cells, and diagnose acute promyelocytic leukemia.

The application discloses a sample detection device and a sample detection method. In the sample detection device, a pipette needle assembly is used to suck and spit the sample; a glycosylation detection module is used to perform glycosylation detection on the sample; a blood routine detection module is used to perform blood routine detection on the sample; and a control module is used to control the pipette needle assembly to collect a first sample and a second sample, so that the first sample and the second sample are temporarily stored in the pipette needle assembly at the same time; the pipette needle assembly is controlled to perform first sample separation work and second sample separation work in sequence, or the pipette needle assembly is controlled to perform the second sample separation work and the first sample separation work in sequence; and before the pipette needle assembly performs the first sample separation work, a glycosylation hemolytic agent is used to clean the pipette needle assembly. Based on the above mode, the possibility of cross contamination between blood routine detection and glycosylation detection can be reduced, and the reliability of sample detection is improved.

This disclosure provides a blood analyzer, comprising: a sample aspiration device, a sample preparation device, an optical detection device, and a processor. The blood analyzer performs a first detection on a portion of a blood sample via a DIFF channel. The processor is configured to obtain first information characterizing malignant hematological diseases based at least on first scattered light information and first fluorescence information obtained from the first detection. A judgment is made based on the first information characterizing the risk of malignant hematological diseases. When the first information indicates a risk of malignant hematological diseases, the blood analyzer automatically initiates a second detection, treating another portion of the blood sample with a hemolytic agent capable of differentiating the scattered light characteristics of mature and immature leukocytes. The processor is further configured to obtain second information characterizing the risk of malignant hematological diseases based at least on second scattered light information and / or second fluorescence information obtained from the second detection. The blood analyzer can provide rapid and more accurate alarms for malignant hematological diseases while simultaneously saving detection costs and time.

The application discloses a kind of hemolytic agent underdosing judgment method, device, medium and equipment, by obtaining the particle distribution condition of signal intensity in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of signal intensity of each class in the particle distribution condition of

The invention discloses a blood detection device, and relates to the technical field of blood detection, the blood detection device comprises a reagent conveying unit and an integrated specific protein detection module used for specific protein reaction and detection, and the reagent conveying unit is communicated with the integrated specific protein detection module; the reagent conveying unit comprises a specific protein hemolytic agent conveying line, a special cleaning agent conveying line and a common cleaning liquid conveying line; the specific protein hemolytic agent conveying line, the special cleaning agent conveying line and the common cleaning solution conveying line share one power source. According to the reagent conveying unit, a power source is utilized for conveying a specific protein hemolytic agent and a special cleaning solution, the liquid path principle can be simplified, and the instrument development cost is reduced.